IFNG and autoimmune hepatitis: We have documented therapeutic efficacy in spontaneously hyperglycemic nonobese diabetic (NOD) mice, in C57BL/6 mice with experimental autoimmune encephalomyelitis (EAE), in HLA-DR4-transgenic C57BL/10.M mice with experimental arthritis (2), and more recently, NOD.c3c4, C57BL/6.Ifng-Δ-ARE+/– and NOD.Abcb4–/– mice with spontaneous primary biliary or sclerosing cholangitis (PBC and PSC, respectively), and NOD and C57BL/6 mice with experimental autoimmune hepatitis (AIH) (3, 4).